HHS sends peptide access policy to White House for review

The short version

• HHS submitted a peptides interim access policy to the White House for review, and the plan was sent to the Office of Management and Budget.[Associated Press · ABC News]
• Two anonymous sources say the plan would let specialty pharmacies temporarily compound popular peptides such as BPC-157.[Associated Press · ABC News]
• The FDA previously listed BPC-157 and over a dozen other injectable peptides as too risky for compounding, and staff say safety data are lacking.[Associated Press]
• Formal FDA rulemaking to add peptides could take years, and it is unclear whether the administration will pursue it.[Associated Press]

Key facts

• HHS submitted a peptides interim access policy to the White House for review, according to a Thursday government website posting.[Associated Press · ABC News]
• The plan was sent to the Office of Management and Budget, which reviews federal rules with potential significant economic impact.[Associated Press · ABC News]
• Two people familiar with the plan, speaking anonymously, say it would let pharmacies temporarily compound some popular peptides, including BPC-157.[Associated Press]
• The FDA previously placed BPC-157 and more than a dozen other injectable peptides on its list of substances too risky to be compounded.[Associated Press]
• FDA staff scientists said none of the peptides had been studied enough to establish safety and effectiveness.[Associated Press]
• Formally adding peptides to the FDA safe-for-compounding list would require federal rulemaking that could take years.[Associated Press]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.

• Trump administration advances plan for peptide drugs favored by RFK Jr.Associated Press · Wire: associated-press
• Trump administration advances plan for peptide drugs favored by RFK Jr.ABC News - Business